Thomas J Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, discusses the importance of better identifying mechanisms of resistance to targeted therapies in chronic lymphocytic leukemia (CLL), and how novel agents aim to overcome this challenge. Dr Kipps further explains how next-generation Bruton’s tyrosine kinase (BTK) inhibitors, such as acalabrutinib and zanubrutinib, have shown promise in this space, and highlights the importance of finding the best combination strategies to treat patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.